Medical/Pharmaceuticals

China Medical System (867.HK)'s Latest MSCI ESG Rating Unchanged at AA, Leading the Industry Globally

HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company").CMS's latest rating remains uncha...

2021-12-30 20:00 3110

Peijia Medical's New Milestone Asia's first successful clinical case using HighLife transseptal mitral valve replacement technology

SUZHOU, China, Dec. 30, 2021 /PRNewswire/ -- On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement ("TSMVR") technology was successfully carried out inAsia. The implantation of Peijia's Highlife TSMVR system was performed by ProfessorMao Chen and his te...

2021-12-30 19:18 4814

Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

SHANGHAI and HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life...

2021-12-30 09:51 5017

iMEDISYNC UNVEILS WORLD'S FIRST INTEGRATED WIRELESS BRAIN EEG at CES 2022

SEOUL, South Korea, Dec. 29, 2021 /PRNewswire/ -- iMediSync, a leading AI-driven early detection and therapeutic platform for optimal brain health from Seoul, South Korea announced today that the company will showcase its comprehensive EEG solution (hardware + software + remote telehealth solution...

2021-12-30 00:00 3912

SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical

SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Appro...

2021-12-29 20:30 3144

Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane

* On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage * Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries includingItal...

2021-12-29 19:00 5350

DoctorOnCall Offers Free Medical Assistance To Flood Victims

KUALA LUMPUR, Malaysia, Dec. 29, 2021 /PRNewswire/ -- Amidst Malaysia's worst flash flooding following heavy rains over the weekend that displaced tens of thousands of people,Malaysia's first and largest digital health platform, DoctorOnCall, has announced a flood relief medical assistance initia...

2021-12-29 11:30 4958

Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China

GUANGZHOU, China, Dec. 29, 2021 /PRNewswire/ -- The inauguration ceremony of Biosyngen Pte. Ltd., ("Biosyngen") joint projects and Biosyngen biological production base was held inChina-Singapore Guangzhou Knowledge City (CSGKC), on December 28th , 2021.

2021-12-29 10:00 6878

VISTA Eye Specialist resolved to be a Changemaker and A Force for Good with B Corp Certification.

PETALING JAYA, Malaysia, Dec. 29, 2021 /PRNewswire/ -- VISTA Eye Specialist (VISTA) believes that being one of the leading eye specialists is not just about medical care. "As part of our mission statement, we believe that other than to safely help people see their best, our goal is about changing...

2021-12-29 08:00 3284

2020 Global Survey from ISAPS Sees Significant Changes in Aesthetic Procedures During Pandemic

COVID-19 practice closures lead to a 10.9% decrease in surgical procedures WEST LEBANON, N.H., Dec. 28, 2021 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, which showcased the ...

2021-12-28 22:05 2018

EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH

* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...

2021-12-28 22:00 2612

Muslim-Friendly Malaysia Showcases Healthcare Excellence at Expo 2020 Dubai

DUBAI, UAE, Dec. 28, 2021 /PRNewswire/ -- Malaysia Healthcare, will be showcasing its excellence in healthcare service delivery and providing seamless healthcare journey experiences during Week 14 of Expo 2020 Dubai. From 2nd - 8th January 2022, expo participants can visit the Malaysia Pavilion to...

2021-12-28 15:00 2329

Akeso's IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS

HONG KONG, Dec. 27, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab  (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed. Such clinical trial aims to evalua...

2021-12-28 12:30 2853

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company,announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, smal...

2021-12-28 09:00 2060

CStone announced new drug approval of precision therapy AYVAKIT® (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST)

* AYVAKIT is the first precision therapy approved in Hong Kong, China for the treatment of patients with PDGFRA D842V mutant GIST * This is CStone's fifth NDA approval in Greater China this year SUZHOU, China ,Dec. 28, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2021-12-28 08:00 4970

Lunit Obtains MDSAP Certificate, Granted Fast-Track Regulatory Process in Major Countries

* Lunit meets MDSAP requirements as a global standard medical AI software manufacturer * QMS audit exemption in the US, Canada, Japan, Australia, and Brazil SEOUL, South Korea, Dec. 27, 2021 /PRNewswire/ -- Lunit, a leading AI software company for cancer screening and treatment, announced it ...

2021-12-27 23:00 3146

ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron

Avifavir® is effective against various variants of coronavirus, including Delta and Omicron, as it affects the highly conservative and mutation-resistant replication systems of RNA virus (RdRp). The virus is incapable of developing resistance to favipiravir even with long-term exposure on infect...

2021-12-27 21:20 3861

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Dec. 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation (CDE) ofChina's National ...

2021-12-27 21:00 2724

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

SUZHOU, China, Dec. 27, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatme...

2021-12-27 20:19 3178

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

DURHAM, N.C. and BEIJING, Dec. 27, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-12-27 18:45 4853
1 ... 614615616617618619620 ... 644